Mar 18 |
Taysha Gene Therapies Q4 2023 Earnings Preview
|
Mar 14 |
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
|
Feb 29 |
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
|
Feb 15 |
Taysha transfers rights to 3 programs, extends cash runway into 2026
|
Feb 15 |
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
|
Feb 13 |
Owning 39% shares,institutional owners seem interested in Taysha Gene Therapies, Inc. (NASDAQ:TSHA),
|
Feb 6 |
Taysha: Produces Solid Data But Has Abandoned Programs
|
Jan 31 |
7 Micro-Cap Stocks That Could Majorly Surprise Investors
|
Jan 22 |
Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference
|
Jan 15 |
3 Growth Stocks That Could Go Parabolic in 2024
|